A randomised phase II study of sunitinib versus dacarbazine in the treatment of patients with metastatic uveal melanoma

Registry ID

EUCTR2008-008794-55

Source registry

EUCTR

Status

Completed

Phase

PHASE2

Sponsor

The Clatterbridge Cancer Centre NHS Foundation Trust

Start date

2010-04-14

Completion date

2014-02-15

Last update

2026-08-16

Conditions

• Metastatic Uveal Melanoma

Summary

Can the progression free survival time of patients with metastatic Uveal Melanoma be extended by treatment with Sunitinib, compared with the treatment by Dacarbazine?

Locations

• , , UK

Related clinical trials

• Tebentafusp-tebn With LDT in Metastatic UM
• A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, Dedifferentiated Liposarcoma, or Angiosarcoma
• Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions
• Dual-Target CSPG4/GD2 CAR-NK Cells for Advanced Melanoma
• A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
• Phase 2 Combination of Melphalan/HDS Via PHP + Tebentafusp in Treating Metastatic Uveal Melanoma

View on source registry